Published in final edited form as:

J Am Chem Soc. 2011 May 25; 133(20): 7648–7651. doi:10.1021/ja2006719.

Labeling Substrates of Protein Arginine Methyltransferase with Engineered Enzymes and Matched S-Adenosyl-L-methionine Analogues

Rui Wang^{1,2}, Weihong Zheng¹, Haiqiang Yu³, Haiteng Deng^{3,4}, and Minkui Luo^{1,2}

Minkui Luo: luom@mskcc.org

¹Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065

²Program of Pharmacology, Weill Graduate School of Medical Science, Cornell University, New York, NY 10021

³Proteomics Resource Center, Rockefeller University, New York, NY 10065

⁴School of Life Sciences, Tsinghua University, Beijing, 100084 China

Abstract

Elucidating physiological and pathogenic functions of protein methyltransferases (PMTs) relies on knowing their substrate profiles. S-adenosyl-L-methionine (SAM) is the sole methyl-donor cofactor of PMTs. Recently, SAM analogues have emerged as novel small-molecule tools to label PMT substrates. Here we reported the development of a clickable SAM analogue cofactor, 4-propargyloxy-but-2-enyl SAM, and its implementation to label substrates of human protein arginine methyltransferase 1 (PRMT1). In the system, the SAM analogue cofactor, coupled with matched PRMT1 mutants rather than native PRMT1, was shown to efficiently label PRMT1 substrates. The transferable 4-propargyloxy-but-2-enyl moiety of the SAM analogue further allowed corresponding modified substrates to be characterized through a subsequent click chemical ligation with an azido-based probe. The SAM analogue, in combination with a rational protein-engineering approach, thus demonstrates potential to label and identify PMT targets in the context of a complex cellular mixture.

Protein arginine methyltransferases (PRMTs) catalyze arginine methylation of a broad range of substrates.^{1,2} PRMTs use the cofactor S-adenosyl-L-methionine (SAM, **1**, Fig. 1) as a methyl donor to modify arginine's guanidino nitrogen in three ways: monomethylation, asymmetric dimethylation (type I PRMTs) and symmetric dimethylation (type II PRMTs).³ The biological consequences of arginine methylation have been implicated in multiple cellular events, such as signal transduction, transcriptional regulation, mRNA splicing and protein translocation.^{2,4-7} The dysregulation of protein arginine methyltransferases has also been linked to various diseases including cancer.² Among 11 known human PRMTs,² PRMT1 and PRMT6 are overexpressed in many clinical cancer tissues;⁸ PRMT4 is upregulated significantly in breast tumors and hormone-dependent prostate tumors;^{9,10} PRMT5 acts as a prosurvival factor by downregulating tumor suppressors ST7 and NM23 in fibroblast cells.¹¹ Although the importance of the physiological and pathogenic roles of PRMTs is well known, how PRMTs recognize their substrates in a cellular context remains to be elucidated.^{12,13}

Correspondence to: Minkui Luo, luom@mskcc.org.

Supporting Information **Available:** Experimental procedures, synthetic methods, and supplementary figures.

To profile substrates of designated protein methyltransferases (PMTs), some prior approaches relied on recombinant enzymes and radiolabeled SAM with a PMT-knockout proteome or peptide array libraries as substrate candidates.¹⁴⁻¹⁶ Recently, SAM analogues, particularly those carrying transferable chemical reporters (terminal alkynyl, keto or amino groups), have emerged as novel small-molecule tools to examine methyltransferases and label their substrates.¹⁷⁻²⁵ For instance, several aziridinium-based SAM analogues have been applied to label the targets of DNA and protein methyltransferases.²⁰⁻²³ Given the potential product inhibition of aziridinium-based SAM cofactors,²² double-activated SAM analogues that contain alkenyl/alkynyl/keto-activated sulfonium carbons have been further developed.^{17,19,25,26} Some recent successes include using (*E*)-pent-2-en-4-ynyl (**4**, Fig. 1), propargyl and keto SAM analogues to label the substrates of MLL4, SETDB1 and catechol *O*-methyltransferase, respectively.¹⁷⁻¹⁹ However, emerging evidence also suggests that SAM analogues may only act as cofactors for certain methyltransferases.¹⁹ For instance, propargyl SAM is a cofactor of SETDB1 but not SET7/9, SMYD2, PRMT4 and PRMT1.¹⁹ This observation therefore triggered us to develop SAM analogues that, though may not be active for native PMTs, can be used by engineered PMTs for substrate labeling (Fig. 1). This approach is expected to expand the capability of SAM analogues as small-molecule tools to label the targets of designated PMTs.

To identify such cofactors, a panel of SAM analogues were synthesized (Fig. 1). These compounds include allyl SAM **2** and (*E*)-pent-2-en-4-ynyl SAM **4**, which were identified first as active cofactors of DNA adenine-N6 methyltransferase M.TaqI and human MLL4, respectively.^{17,26} Using similar synthetic strategies,^{20,26} 4-pentynyl SAM **3** and 4-propargyloxy-but-2-enyl SAM **5** (Pob-SAM) were also prepared (Fig. 1 and Supporting Information). The latter two SAM analogues, as well as **4**, are featured by a terminal alkynyl group, which can serve as a clickable reporter of azido-based probes.²⁷⁻²⁹ Among these synthetic SAM derivatives, **2** and **4** have a sulfonium- β vinyl moiety, which favors S_N2 -like transition states of methyltransferases,^{17,26} and **3** contains an ethylene linker. Pob-SAM **5** mimics **2** except that it contains an additional methylene-glycol linker. Propargyl SAM was reported to be active for certain methyltransferases.^{19,30} However, its rapid decomposition, as noticed by others and confirmed by us (data not shown),¹⁷ prevented us from examining propargyl SAM further.

PRMT1 is the predominant type I human PRMT and accounts for 80% of total human PRMT activity.³¹ Here human PRMT1 was chosen as a model enzyme to examine the activities of the SAM analogues as cofactors. SAM, SAM derivatives **3** and **5**, as well as previously-reported active cofactors **2** and **4**,^{17,26} were first tested against native PRMT1. After incubating these compounds with PRMT1 and its RGG peptide substrate,^{12,13,32} the products were analyzed by HPLC-MS to trace desirable modifications. Although native SAM and **2** can be utilized by native PRMT1, none of the clickable SAM analogues (**3-5**) showed detectable activity toward native PRMT1 and the RGG substrate (Figs. 2a and S1).

Given the undetectable activity of the clickable SAM analogues **3-5** on the RGG substrate with native PRMT1, the feasibility of the SAM analogues to be accommodated by engineered PRMT1 was then explored (Fig. 3). Similar approaches have been applied to other enzymes, particularly kinases, for target labeling.³³ Analysis of SAM-binding pockets of PRMT1 and other PRMTs (Fig. 3a) reveals several conserved residues (Y35, F36, Y39, M48 and D51 of PRMT1).³² Since Y39 and M48 of PRMT1 are in close proximity to SAM's sulfonium methyl group, as a proof-of-principle approach, the two residues were replaced with less-sterically-hindered amino acids (Y39G, A, V, L, F and M48G, A, V, L, Fig. 3b), a strategy expected to expand PMT SAM-binding pockets.³⁴ After screening the mutants, native SAM was shown to be active toward the panel of PRMT1 single mutants. In contrast, analogue **2** and **5** were shown to be active toward Y39F, Y39L mutants and the

M48G mutant, respectively (Figs. 2 and S1). To further boost the selectivity of SAM analogues, two double mutants were generated by combining the most active single mutants (Fig. 2a). Although SAM and SAM analogues **2–4** are inert to the double mutants, Pob-SAM **5** exhibited excellent activity toward the Y39FM48G PRMT1 mutant (Fig. 2 and S1).

To further examine the catalytic efficiency of the Y39FM48G PRMT1 mutant on Pob-SAM **5**, the apparent k_{cat} and $K_{\text{m,Pob-SAM}}$ of the enzyme-cofactor pair were measured (Supporting Information and Fig. S5). Although the $K_{\text{m,Pob-SAM}}$ of 63 μM for the PRMT1 mutant is 3-fold higher than $K_{\text{m,SAM}}$ (21 μM) of native PRMT1 and the $k_{\text{cat}}/K_{\text{m,Pob-SAM}}$ ($1.4 \times 10^3 \text{ M}^{-1} \text{ min}^{-1}$) is around 20-fold lower than that of native PRMT1 and SAM ($2.6 \times 10^4 \text{ M}^{-1} \text{ min}^{-1}$),³⁵ the engineered enzyme-cofactor pair has gained sufficient activities to label PRMT1 targets (see results below).

Given the distinct reactivity of Pob-SAM **5**, we further explored the mechanism that Pob-SAM **5**, rather than **3** and **4**, is favored as a cofactor by the PRMT1 Y39FM48G mutant. Our competition results showed that **3** and **4** inhibit the reaction of PRMT1 Y39FM48G mutant and Pob-SAM **5** with an IC_{50} of 4–6 μM (see Fig. S5 and supporting information). This observation suggests that **3** and **4** indeed bind to the PRMT1 mutant but fail to be processed further. Since Pob-SAM **5** differs from **4** only by a methylene-glycol linker, this moiety must render some steric or electronic effects to promote the chemical conversion of Pob-SAM **5** by the engineered PRMT1. Although follow-up studies are needed to further elucidate the origin of the distinct reactivity of PRMT1 Y39FM48G mutant on Pob-SAM **5**, the successful identification of the matched cofactor-enzyme pair, as well as its robust activity, presents a suitable system for substrate labeling.

After confirming the activity of Pob-SAM **5** on PRMT1 RGG peptide substrate, its activity on other substrates was examined. Using the full-length histone H4 and histone octamer as substrates, Pob-SAM **5** was shown to be utilized efficiently by the PRMT1 Y39FM48G mutant with the desirable 4-propargyloxy-but-2-enylation delivered to histone H4 arginine 3 (H4R3), the reported H4 methylation site of native PRMT1,^{2,13,35,36} but not H2A, H2B, H3 and other arginines on H4 (Figs. 4 and S2, MS and MS/MS data). A competition assay was also performed by incubating H4 and the PRMT1 mutant with both Pob-SAM **5** and SAM. Consistent with the RGG substrate (Table 1), histone H4 was solely modified by Pob-SAM **5** but not SAM (4-propargyloxy-but-2-enylation versus no methylation, Fig S3). The lack of the activity of PRMT1 Y39FM48G mutant on native SAM was also confirmed by using the histone H4 (1-21) peptide as a substrate (Fig. S4). In contrast, native PRMT1 and its Y39F, Y39L, M48G mutants can process native SAM and H4 to various extents (Fig. S4). The bioorthogonal character of Pob-SAM **5** and PRMT1 Y39FM48G mutant thus makes the cofactor-enzyme pair suitable for substrate labeling even in the presence of native SAM.

Given the clickable feature of the terminal-alkyne of Pob-SAM **5**, we further examined whether the alkynyl functionality can be implemented for substrate characterization in combination with Cu(I)-catalyzed click chemical ligation. Full-length histone H4 was treated with Pob-SAM **5** in the presence of the Y39FM48G PRMT1 mutant as well as enzyme- and cofactor-negative controls. The products were then reacted with an azido-rhodamine fluorescent probe, followed by gel electrophoresis separation and in-gel fluorescence visualization. A specific fluorescent band was detected only for the H4 treated with Pob-SAM **5** and the Y39FM48G PRMT1 mutant (Fig. 5b). In contrast, the control experiments in the absence of Pob-SAM **5** or the active PRMT1 mutant did not exhibit significant labeling (Fig. 5b). To further prove that Pob-SAM **5** and the matched PRMT1 mutant are efficient to label potential PRMT1 targets in the context of complex cellular proteome, the hypomethylated lysate of HEK293T cells were used as protein substrates and treated with the mutant-cofactor pair. The resultant modified proteome was then subject to

azido-rhodamine labeling. In comparison with the enzyme-negative control, multiple new protein bands can be visualized readily through in-gel fluorescence (Lane 2 versus Lane 1 in Fig. 5c). The substrate-labeling activity of Pob-SAM **5** is high specific for Y39FM48G PRMT1 mutant because neither native PRMT1 nor a dead PRMT1 mutant exhibited such a labeling pattern. Although the newly-labeled protein bands remain to be characterized by MS and validated through vigorous *in vitro* and *in vivo* assays using native PRMT1 and SAM, the current finding has demonstrated the potential to implement Pob-SAM in combination with engineered methyltransferases to identify PRMT1 targets.

Here Pob-SAM **5** was successfully identified as a clickable SAM analogue cofactor that can be utilized by engineered human PRMT1 but not by native PRMT1 for substrate labeling. It was reported previously that adenine-N6-derivatized SAM analogues can serve as bioorthogonal cofactors of engineered Rmt1 (a yeast PRMT). Since the adenine-derivatized SAM analogue cofactors still maintain the sulfonium methyl moiety of SAM, these SAM derivatives can only be used as methyl donors. The chemically-inert methylation is less ready to be probed than clickable modifications, since the latter can be further coupled with Cu(I)-catalyzed chemical ligation for target identification (e.g. Pob-SAM **5**). A clickable aziridinium-based SAM analogue was also reported to modify PRMT1 substrates.²² In that case, the cofactor-substrate adduct inhibits PRMT1 and thus prevents multiple turnover.²² The present work successfully circumvents these limitations by developing Pob-SAM **5**, which carries a transferable, clickable functionality and meanwhile can be processed enzymatically. The combined features are useful to label and identify PRMT1 substrates from cellular proteome through the enzymatic installation of a clickable reporter, followed by a click ligation to suitable analytic tags. More importantly, accessing Pob-SAM **5** for engineered PRMT1 can be a starting point to engineer other structurally-related PRMTs¹⁻³ to utilize the same cofactor. Another potential application of Pob-SAM **5** is to evolve bioorthogonal cofactor-enzyme pairs and apply them to dissect the substrates of designated PMTs, such as PRMT1, in the context of closely related PMTs.

Unveiling the substrates of PRMTs is of great importance to understanding their biological functions.¹⁻³ Here we developed a SAM analogue cofactor in combination with a rational protein-engineering approach to label PRMT1 substrates. The clickable feature of the cofactor further facilitates subsequent substrate characterization. In combination with Cu-catalyzed click chemistry and MS analysis, this system is expected to have the ability to identify PMT substrates from complex cellular mixtures. The new SAM analogue cofactor therefore expands our chemical tools to identify novel PMT targets.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Authors thank Dr. Paul Thompson for human PRMT1 plasmid; Jamie McBean and Christina Crump for critical comments on the manuscript. This work was supported by the V Foundation for Cancer Research through 2009 V Foundation Scholar Award and NIH through NIGMS (1R01GM096056-01) and the NIH Director's New Innovator Award Program (1-DP2-OD007335-01). This work is dedicated to Prof. David Gin for his role as a respected scientist, colleague and mentor.

References

1. Bedford MT, Richard S. Mol Cell. 2005; 18:263. [PubMed: 15866169]
2. Bedford MT, Clarke SG. Mol Cell. 2009; 33:1. [PubMed: 19150423]
3. Bedford MT. J Cell Sci. 2007; 120:4243. [PubMed: 18057026]

4. Aletta JM, Cimato TR, Ettinger MJ. *Trends Biochem Sci.* 1998; 23:89. [PubMed: 9581497]
5. Xu W, Chen H, Du K, Asahara H, Tini M, Emerson BM, Montminy M, Evans RM. *Science.* 2001; 294:2507. [PubMed: 11701890]
6. Gary JD, Clarke S. *Prog Nucleic Acid Res Mol Biol.* 1998; 61:65. [PubMed: 9752719]
7. Nichols RC, Wang XW, Tang J, Hamilton BJ, High FA, Herschman HR, Rigby WF. *Exp Cell Res.* 2000; 256:522. [PubMed: 10772824]
8. Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, Nakamura Y, Hamamoto R. *Int J Cancer.* 2011; 128:562. [PubMed: 20473859]
9. Kim YR, Lee BK, Park RY, Nguyen NT, Bae JA, Kwon DD, Jung C. *BMC Cancer.* 2010; 10:197. [PubMed: 20462455]
10. Fietze S, Lupien M, Silver PA, Brown M. *Cancer Res.* 2008; 68:301. [PubMed: 18172323]
11. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S. *Mol Cell Biol.* 2004; 24:9630. [PubMed: 15485929]
12. Fronz K, Otto S, Kolbel K, Kuhn U, Friedrich H, Schierhorn A, Beck-Sickinger AG, Ostareck-Lederer A, Wahle E. *J Biol Chem.* 2008; 283:20408. [PubMed: 18495660]
13. Wooderchak WL, Zang TZ, Zhou ZS, Acuna M, Tahara SM, Hevel JM. *Biochemistry.* 2008; 47:9456. [PubMed: 18700728]
14. Rathert P, Dhayalan A, Ma HM, Jeltsch A. *Mol Biosystems.* 2008; 4:1186.
15. Rathert P, Zhang X, Freund C, Cheng XD, Jeltsch A. *Chem Biol.* 2008; 15:5. [PubMed: 18215768]
16. Rathert P, Dhayalan A, Murakami M, Zhang X, Tamas R, Jurkowska R, Komatsu Y, Shinkai Y, Cheng XD, Jeltsch A. *Nat Chem Biol.* 2008; 4:344. [PubMed: 18438403]
17. Peters W, Willnow S, Duisken M, Kleine H, Macherey T, Duncan KE, Litchfield DW, Luscher B, Weinhold E. *Angew Chem Int Ed.* 2010; 49:5170.
18. Lee BW, Sun HG, Zang T, Kim BJ, Alfaro JF, Zhou ZS. *J Am Chem Soc.* 2010; 132:3642. [PubMed: 20196537]
19. Binda O, Boyce M, Rush JS, Palaniappan KK, Bertozzi CR, Gozani O. *Chembiochem.* 2010
20. Dalhoff C, Lukinavicius G, Klimasauakas S, Weinhold E. *Nat Protocols.* 2006; 1:1879.
21. Lukinavicius G, Lapiene V, Stasevskij Z, Dalhoff C, Weinhold E, Klimasauskas S. *J Am Chem Soc.* 2007; 129:2758. [PubMed: 17309265]
22. Osborne T, Roska RL, Rajski SR, Thompson PR. *J Am Chem Soc.* 2008; 130:4574. [PubMed: 18338885]
23. Pljevaljcic G, Pignot M, Weinhold E. *J Am Chem Soc.* 2003; 125:3486. [PubMed: 12643710]
24. Weller RL, Rajski SR. *Chembiochem.* 2006; 7:243. [PubMed: 16365907]
25. Motorin Y, Burhenne J, Teimer R, Koynov K, Willnow S, Weinhold E, Helm M. *Nucleic Acids Res.* 2010
26. Dalhoff C, Lukinavicius G, Klimasauskas S, Weinhold E. *Nat Chem Biol.* 2006; 2:31. [PubMed: 16408089]
27. Grammel M, Zhang MZM, Hang HC. *Angew Chem Int Ed.* 2010; 49:5970.
28. Prescher JA, Bertozzi CR. *Nat Chem Biol.* 2005; 1:13. [PubMed: 16407987]
29. Raghavan AS, Hang HC. *Drug Discov Today.* 2009; 14:178. [PubMed: 18973827]
30. Stecher H, Teng M, Ueberbacher BJ, Remler P, Schwab H, Griengl H, Gruber-Khadjawi M. *Angew Chem Int Ed.* 2009; 48:9546.
31. Tang J, Frankel A, Cook RJ, Kim S, Paik WK, Williams KR, Clarke S, Herschman HR. *J Biol Chem.* 2000; 275:7723. [PubMed: 10713084]
32. Zhang X, Cheng X. *Structure.* 2003; 11:509. [PubMed: 12737817]
33. Bishop AC, Buzko O, Shokat KM. *Trends Cell Biol.* 2001; 11:167. [PubMed: 11306297]
34. Klimasauskas S, Weinhold E. *Trends Biotechnol.* 2007; 25:99. [PubMed: 17254657]
35. Obianyo O, Osborne TC, Thompson PR. *Biochemistry.* 2008; 47:10420. [PubMed: 18771293]
36. Osborne TC, Obianyo O, Zhang X, Cheng X, Thompson PR. *Biochemistry.* 2007; 46:13370. [PubMed: 17960915]

37. Lin Q, Jiang FY, Schultz PG, Gray NS. *J Am Chem Soc.* 2001; 123:11608. [PubMed: 11716715]

Figure 1.

SAM analogues combined with protein-engineering approach to label PRMT1 substrates. The SAM-binding pocket of PRMT1 will be rationally modified to utilize a clickable SAM analogue for substrate labeling. The resultant clickable modification can further react with an azido-based probe for substrate characterization. * PRMT1 mutants.

Figure 2.

(a) Enzymatic activity of PRMT1 and its mutants on RGG peptide substrate with SAM analogues as cofactors (SAM, **1** and SAM analogues **2–5**). Letters “m” and “d” refer to mono- and di-modifications. Color boxes code for percentages of modification under our assay conditions; “ND” means nondetectable with the current MS assay. (b) Representative LC-ESI mass spectra of RGG peptide 4-propargyloxy-but-2-enylated by M48G and Y39FM48G PRMT1 mutants, respectively. Given that the alkylation does not affect the ionization efficiency of the RGG peptide (Figure S1B), the co-eluted LC-MS peaks of the unmodified and modified peptides were co-integrated to obtain the mass ratios and calculated the percentage of conversion (see supporting information for details).

Figure 3.

(a) A hypothetical transition-state structure of PRMT1-catalyzed methylation. The key contact residues were constructed according to the crystal structures of human PRMT1 (PDB file: 1OR8), human PRMT3 (PDB file: 2FYT) and mouse PRMT4 (PDB file: 3B3F). (b) Sequence alignment of human PRMT1, PRMT3 and PRMT4 with the conserved residues highlighted. Y39 and M48 of human PRMT1 are highlighted in red, given their proximity to SAM as shown in Fig. 3a. The two residues were replaced with less-bulky amino acids to adapt SAM analogue cofactors.

Figure 4.

(a) Schematic representation of the reaction of PRMT1 Y39FM48G mutant, Pob-SAM cofactor **5** and human histone H4 substrate. (b) ESI-MS spectrum of the modified H4. (c) Tandem mass spectrum of a characteristic H4R3 fragment.

Figure 5.

(a) H4 modification by PRMT1 Y39FM48G mutant and Pob-SAM 5, followed by click ligation and in-gel fluorescence analysis. (b) In-gel fluorescence of 4-propargyloxy-but-2-enylated histone H4. Recombinant human histone H4 was modified as described (Fig. 5a and Supporting Information). The strong in-gel fluorescence was detected for the sample treated with Y39FM48G mutant (lane 4), but barely detectable for native PRMT1 (Lane 5) and undetectable for other controls (H4-negative, cofactor-negative, enzyme-negative and the dead PRMT1 M48A mutant). Coomassie Blue loading controls (CB) were shown in the bottom panel. *This weak labeling might be due to slightly residual activity of native PRMT1 on Pob-SAM 5 only when pure H4 was used as a substrate. No such labeling has been observed for the RGG peptide (Fig. 2) or the hypomethylated cell lysate (Lane 2 versus Lane 3 in Fig. 3c). (c) In-gel fluorescence of the hypomethylated HEK293T cell extraction treated with Pob-SAM 5 followed by an azido-rhodamine probe. Multiple protein bands were visualized robustly for the sample treated with Pob-SAM 5 and the Y39FM48G mutant (lane 2) but not the controls (enzyme-negative, native PRMT1 and a dead PRMT1 M48A mutant). See Fig. S6 for Coomassie Blue loading control.